Marta Maccari

Padova, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.

Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.

Journal: Neuro-oncology advances
Published: April 17, 2026

Real-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study.

Real-World Treatment Pathways of Adult Patients with Glioblastoma and Other CNS Tumors: A Population-Based Registry Study.

Journal: Current oncology (Toronto, Ont.)
Published: March 12, 2026

Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.

Targeted and systemic therapies for recurrent adult ependymomas: real-world outcomes from a single institution and concise literature review.

Journal: Frontiers in oncology
Published: November 17, 2025

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Journal: Trials
Published: February 17, 2025

Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.

Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.

Journal: Journal of neuro-oncology
Published: January 27, 2025

Corrigendum to "PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives" [Cancer Treat. Rev. 131 (2024) 102850].

Corrigendum to "PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives" [Cancer Treat. Rev. 131 (2024) 102850].

Journal: Cancer treatment reviews
Published: December 21, 2024

PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives.

PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives.

Journal: Cancer treatment reviews
Published: September 23, 2024

Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage.

Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage.

Journal: Brain communications
Published: June 10, 2024

Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion.

Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion.

Journal: Neuro-oncology advances
Published: June 07, 2024

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.

Journal: ESMO open
Published: February 20, 2024

The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.

The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.

Journal: Journal of neuro-oncology
Published: December 30, 2023

Spinal ependymoma in adults: from molecular advances to new treatment perspectives.

Spinal ependymoma in adults: from molecular advances to new treatment perspectives.

Journal: Frontiers in oncology
Published: September 24, 2023
Showing 1-12 of 15

Last Updated: 09/26/2026